Showing results (321-330 of 404) with videos related to

Sort By:
Pageof 41
Bone Marrow Transplantation|January 8, 2013
Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCTT Daikeler, M Mauramo, A Rovó, et al.
Blood|March 1, 1992
Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantationT De Witte, A Gratwohl, N Van Der Lely, et al.
Acta Haematologica|August 7, 1999
High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia--A possible role of high endogenous IL-2 in their suppressionC Nissen, A Tichelli, A Gratwohl, et al.
Blood|May 15, 1996
High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantationD E Speiser, J M Tiercy, N Rufer, et al.
The New England Journal of Medicine|February 1, 1996
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantationE Goulmy, R Schipper, J Pool, et al.
Leukemia|March 1, 1997
Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT)J Y Cahn, M Labopin, A Schattenberg, et al.
Clinical and Experimental Immunology|November 1, 1985
The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantationA M Würsch, J W Gratama, J M Middeldorp, et al.
Bone Marrow Transplantation|September 4, 2003
Quality control of a national bone marrow donor registry: results of a pilot study and proposal for a standardized approachJ-M Tiercy, S Stadelmann, B Chapuis, et al.
Blood|August 1, 1997
Allogeneic blood stem cell transplantation: considerations for donorsP Anderlini, M Körbling, D Dale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)M Fopp, M F Fey, M Bacchi, et al.
Pageof 41